Monday, July 1, 2024

Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer

Related stories

Beroe Makes Strategic Investment in Forestreet, Strengthening AI Capabilities and Driving Procurement Intelligence Innovation

Deal builds out Beroe's leadership in category-level procurement intelligence, with the addition...

Marvell Extends Connectivity Leadership With Industry’s First 1.6T PAM4 DSP for Active Electrical Cables

Marvell Technology, Inc., a leader in data infrastructure semiconductor...

Trellix Named an XDR Market Leader

Trellix Platform excels in scalability, flexibility, and integration capabilities...
spot_imgspot_img

Danaher Corporation, a global science and technology innovator, announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role.

Jose-Carlos Gutierrez-Ramos, Senior Vice President and Chief Science Officer, Danaher, said: “We are delighted to welcome Dr. Stumpe to our team. His extensive experience in leveraging AI to drive scientific and operational progress will be critical in further supporting Danaher’s AI and data strategy to advance innovation.”

Also Read: SCIEX and Mass Analytica Collaborate to Advance Artificial Intelligence Quantitation Software

Dr. Stumpe most recently served as Chief of AI at Tempus, where he spearheaded AI initiatives aiming to make precision medicine a reality. Prior to Tempus, he founded the Cancer Pathology project at Google – which aimed to enhance the accuracy of cancer detection and grading using AI techniques – and was part of the Kepler team at NASA’s Ames Research Center. Dr. Stumpe holds a Ph.D. in Computational & Theoretical Physics from the Max Planck Institute for Biophysical Chemistry in Germany. He will report to Dr. Gutierrez-Ramos.

Danaher is increasingly focusing on AI through inorganic investment, strengthening internal capabilities, and collaborating with leading academic institutions. In December, the company will host the third annual Danaher Summit, bringing together visionary leaders and innovators to discuss AI’s potential impact on biopharmaceutical research and development.

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img